Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation

I. Avivi, S. Chakrabarti, P. Kottaridis, C. Kyriaku, A. Dogan, D. W. Milligan, D. Linch, A. H. Goldstone, S. Mackinnon

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We report the incidence, characteristics and outcome of neurological complications occurring following reduced-intensity conditioning (RIC) in 85 patients who received a related/unrelated donor stem cell transplantation following therapy with alemtuzumab, fludarabine and melphalan. Six patients (probability 8.9%) developed severe neurological complications at a median of 151 days (24-334 days). Five of them presented with progressive peripheral sensori-motor radiculo-neuropathy and/or myelitis, preceded by one or more viral reactivation/infection. Despite treatment with immunoglobulins/plasmapheresis/steroids, four died of respiratory failure due to progressive peripheral neurophathy. Viral infection was identified as the only risk factor for the development of neurological complications. Patients who are treated with alemtuzumab-based RIC may have a lower risk of developing regimen-related neurological complications, but are more susceptible to develop peripheral radiculo-neuropathy or myelitis. This phenomenon may be possibly related to viral infection associated with delayed immunological recovery or immunological dysregulation caused by alemtuzumab-induced T-cell depletion.

Original languageEnglish (US)
Pages (from-to)137-142
Number of pages6
JournalBone Marrow Transplantation
Volume34
Issue number2
DOIs
StatePublished - Jul 2004
Externally publishedYes

Fingerprint

Homologous Transplantation
Virus Diseases
Myelitis
Unrelated Donors
Melphalan
Plasmapheresis
Stem Cell Transplantation
Peripheral Nervous System Diseases
Respiratory Insufficiency
Immunoglobulins
Steroids
T-Lymphocytes
Incidence
Therapeutics
alemtuzumab

Keywords

  • Alemtuzumab
  • Neurological complications
  • Reduced-intensity conditioning

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Avivi, I., Chakrabarti, S., Kottaridis, P., Kyriaku, C., Dogan, A., Milligan, D. W., ... Mackinnon, S. (2004). Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. Bone Marrow Transplantation, 34(2), 137-142. https://doi.org/10.1038/sj.bmt.1704538

Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. / Avivi, I.; Chakrabarti, S.; Kottaridis, P.; Kyriaku, C.; Dogan, A.; Milligan, D. W.; Linch, D.; Goldstone, A. H.; Mackinnon, S.

In: Bone Marrow Transplantation, Vol. 34, No. 2, 07.2004, p. 137-142.

Research output: Contribution to journalArticle

Avivi, I, Chakrabarti, S, Kottaridis, P, Kyriaku, C, Dogan, A, Milligan, DW, Linch, D, Goldstone, AH & Mackinnon, S 2004, 'Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation', Bone Marrow Transplantation, vol. 34, no. 2, pp. 137-142. https://doi.org/10.1038/sj.bmt.1704538
Avivi, I. ; Chakrabarti, S. ; Kottaridis, P. ; Kyriaku, C. ; Dogan, A. ; Milligan, D. W. ; Linch, D. ; Goldstone, A. H. ; Mackinnon, S. / Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation. In: Bone Marrow Transplantation. 2004 ; Vol. 34, No. 2. pp. 137-142.
@article{bba3237b50ac420cade831a165643726,
title = "Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation",
abstract = "We report the incidence, characteristics and outcome of neurological complications occurring following reduced-intensity conditioning (RIC) in 85 patients who received a related/unrelated donor stem cell transplantation following therapy with alemtuzumab, fludarabine and melphalan. Six patients (probability 8.9{\%}) developed severe neurological complications at a median of 151 days (24-334 days). Five of them presented with progressive peripheral sensori-motor radiculo-neuropathy and/or myelitis, preceded by one or more viral reactivation/infection. Despite treatment with immunoglobulins/plasmapheresis/steroids, four died of respiratory failure due to progressive peripheral neurophathy. Viral infection was identified as the only risk factor for the development of neurological complications. Patients who are treated with alemtuzumab-based RIC may have a lower risk of developing regimen-related neurological complications, but are more susceptible to develop peripheral radiculo-neuropathy or myelitis. This phenomenon may be possibly related to viral infection associated with delayed immunological recovery or immunological dysregulation caused by alemtuzumab-induced T-cell depletion.",
keywords = "Alemtuzumab, Neurological complications, Reduced-intensity conditioning",
author = "I. Avivi and S. Chakrabarti and P. Kottaridis and C. Kyriaku and A. Dogan and Milligan, {D. W.} and D. Linch and Goldstone, {A. H.} and S. Mackinnon",
year = "2004",
month = "7",
doi = "10.1038/sj.bmt.1704538",
language = "English (US)",
volume = "34",
pages = "137--142",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Neurological complications following alemtuzumab-based reduced-intensity allogeneic transplantation

AU - Avivi, I.

AU - Chakrabarti, S.

AU - Kottaridis, P.

AU - Kyriaku, C.

AU - Dogan, A.

AU - Milligan, D. W.

AU - Linch, D.

AU - Goldstone, A. H.

AU - Mackinnon, S.

PY - 2004/7

Y1 - 2004/7

N2 - We report the incidence, characteristics and outcome of neurological complications occurring following reduced-intensity conditioning (RIC) in 85 patients who received a related/unrelated donor stem cell transplantation following therapy with alemtuzumab, fludarabine and melphalan. Six patients (probability 8.9%) developed severe neurological complications at a median of 151 days (24-334 days). Five of them presented with progressive peripheral sensori-motor radiculo-neuropathy and/or myelitis, preceded by one or more viral reactivation/infection. Despite treatment with immunoglobulins/plasmapheresis/steroids, four died of respiratory failure due to progressive peripheral neurophathy. Viral infection was identified as the only risk factor for the development of neurological complications. Patients who are treated with alemtuzumab-based RIC may have a lower risk of developing regimen-related neurological complications, but are more susceptible to develop peripheral radiculo-neuropathy or myelitis. This phenomenon may be possibly related to viral infection associated with delayed immunological recovery or immunological dysregulation caused by alemtuzumab-induced T-cell depletion.

AB - We report the incidence, characteristics and outcome of neurological complications occurring following reduced-intensity conditioning (RIC) in 85 patients who received a related/unrelated donor stem cell transplantation following therapy with alemtuzumab, fludarabine and melphalan. Six patients (probability 8.9%) developed severe neurological complications at a median of 151 days (24-334 days). Five of them presented with progressive peripheral sensori-motor radiculo-neuropathy and/or myelitis, preceded by one or more viral reactivation/infection. Despite treatment with immunoglobulins/plasmapheresis/steroids, four died of respiratory failure due to progressive peripheral neurophathy. Viral infection was identified as the only risk factor for the development of neurological complications. Patients who are treated with alemtuzumab-based RIC may have a lower risk of developing regimen-related neurological complications, but are more susceptible to develop peripheral radiculo-neuropathy or myelitis. This phenomenon may be possibly related to viral infection associated with delayed immunological recovery or immunological dysregulation caused by alemtuzumab-induced T-cell depletion.

KW - Alemtuzumab

KW - Neurological complications

KW - Reduced-intensity conditioning

UR - http://www.scopus.com/inward/record.url?scp=4043114880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4043114880&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704538

DO - 10.1038/sj.bmt.1704538

M3 - Article

C2 - 15235576

AN - SCOPUS:4043114880

VL - 34

SP - 137

EP - 142

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 2

ER -